JBC Origene Your Gene Company

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M204698200 on September 26, 2002

J. Biol. Chem., Vol. 277, Issue 48, 46079-46084, November 29, 2002
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/48/46079    most recent
M204698200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Choe, E. Y.
Right arrow Articles by Park, I.-W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Choe, E. Y.
Right arrow Articles by Park, I.-W.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HIV Nef Inhibits T Cell Migration*

Evangeline Y. ChoeDagger, Elena S. SchoenbergerDagger, Jerome E. Groopman§, and In-Woo Park

From the Division of Experimental Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02115

Received for publication, May 14, 2002, and in revised form, September 20, 2002

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Nef is a viral regulatory protein of the human immunodeficiency virus (HIV) that has been shown to contribute to disease progression. Among its putative effects on T cell functions are the down-regulation of CD4 and major histocompatibility class I surface molecules. These effects occur in part via Nef interactions with intracellular signaling molecules. We sought to better characterize the effects of HIV Nef on T cell function by examining chemotaxis in response to stromal cell-derived factor-1alpha (SDF-1alpha ) as well as CXCR4 signaling molecules. Here, we report the novel observation that HIV Nef inhibited chemotaxis in response to SDF-1alpha in both Jurkat T cells and primary peripheral CD4+ T lymphocytes. Our data indicate that HIV Nef altered critical downstream molecules in the CXCR4 pathway, including focal adhesion kinases. These findings suggest that HIV Nef may blunt the T cell response to chemokines. Because T lymphocyte migration is an integral component of host defense, HIV Nef may thereby contribute to the pathogenesis of AIDS.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

HIV1 encodes both structural and regulatory proteins important in the pathogenesis of AIDS. Among the regulatory proteins is Nef, whose role in viral infection and disease progression has been controversial (1-11). Among the putative functions attributed to Nef are the maintenance of high viral load (1) and immune evasion due to its down-regulation of CD4 (2) and MHC I molecules (7). Nef has also been found to protect infected primary T cells against cytotoxic T lymphocytes (3). Although some studies (4-6, 9) have concluded that Nef increases T cell activation, other studies (8, 10-11) indicated that Nef caused decreased T cell activation. Despite these conflicting data, one consistent finding has been that Nef interacts with various signaling molecules, including members of the Src kinase family such as Hck and Lck, the latter a protein tyrosine kinase associated with CD4 and T cell receptor function (12-16); and PAK2, a serine/threonine kinase that modulates the cytoskeletal apparatus (Refs. 17 and 18 and for review see Refs. 19 and 20). Moreover, Nef may affect mediators of apoptosis and thereby foster the longevity of infected cells (18). Recently, Nef was shown to activate ERK1/2 in primary CD4+ T cells obtained from peripheral blood (21). The ERK kinases are members of the MAP kinase family and can participate in a variety of cell functions, including growth and migration (22-26).

In macrophages, the nef gene product has been linked to alterations in chemokine production (6), indicating a possible role of Nef in the regulation of lymphocyte chemotaxis. Furthermore, the capacity of Nef to alter intracellular signaling molecules suggested that mediators of chemotaxis could be affected. To our knowledge, however, there are no reports of Nef affecting T cell chemotaxis. Here we report that HIV Nef significantly inhibited the response of CD4+ T cells to the physiological chemokine stromal cell-derived factor-1alpha (SDF-1alpha ).

SDF-1 is a member of the CXC chemokine family. It was first identified as a pre-B-cell growth-stimulating factor and cloned from mouse bone marrow stromal cells (27). Its two forms, SDF-1alpha and -1beta , arise from a single gene through alternative splicing. Human SDF-1alpha , a 7.8-kDa molecule, is a powerful chemoattractant for T lymphocytes, and its function has been well characterized (28-31). SDF-1alpha binds exclusively to the cell-surface receptor, CXCR4. The CXCR4 molecule is expressed on several cell types, including T lymphocytes, and has been shown to function as a co-receptor for certain strains of HIV (28).

In this study, we present a novel observation of HIV Nef inhibiting CD4+ T lymphocyte chemotaxis and altering critical downstream molecules in the CXCR4 pathway, including cytoskeletal regulatory proteins. These findings suggest that HIV Nef may blunt the T cell response to SDF-1alpha via intracellular disruption of CXCR4 receptor signaling. Because regulated migration of T cells in response to cognate chemotactic ligands is a key component of host defense (32, 33), HIV Nef may act to impair T cell function and contribute to the pathogenesis of AIDS.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Reagents and Antibodies-- Recombinant SDF-1alpha was purchased from R & D Systems (Minneapolis, MN). Purified antibodies to phospho-ERK1/2, phospho-STAT1, PY99, actin, and p85 were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-RAFTK antibody was a generous gift from Dr. Hava Avraham, Division of Experimental Medicine, Beth Israel Deaconess Medical Center, Boston (34). Myelin basic protein and antibody to 4G10 were obtained from Upstate Biotechnology, Inc. (Lake Placid, NY). Bovine serum albumin was obtained from Sigma. Electrophoresis reagents and nitrocellulose membranes were obtained from Bio-Rad.

Creation and Maintenance of Permanent nef-expressing T Cell Lines-- Permanent nef-expressing Jurkat T cell lines were constructed using the Clontech Tet-Off Gene Expression Systems. These cell lines produce GFP or HIV Nef-GFP proteins under Tet-Off control, meaning that gene expression was turned on when tetracycline was removed from the culture medium. The cell lines were cultured in RPMI 1640 medium (Mediatech-Cellgro) containing 10% fetal bovine serum, 1% penicillin/streptomycin, 0.2 mg/ml geneticin (G418), 0.2 mg/ml hygromycin, 2 µg/ml tetracycline (Tet). Gene expression was induced by culturing the cells for 48 h in culture medium without tetracycline.

Purification and HIV Transduction of Primary CD4+ T Cells-- To confirm that the effect of Nef was not restricted to a Jurkat T cell line, effects of nef expression on migration of primary peripheral blood CD4+ T lymphocytes were examined. Briefly, GFP and nef-GFP fusions were cloned in adeno-associated virus (AAV)-derived vector, and recombinant AAV-packaged GFP and nef-GFP were generated at a multiplicity of infection of 1.4 × 1012 and 1.2 × 1012, respectively, from the Harvard Medical School Core Facility. In this system, 1 multiplicity of infection corresponds to 1 virion particle per cell. For isolation of CD4+ T cells, peripheral blood mononuclear cells (PBMC) were isolated from fresh whole blood by density gradient centrifugation with Ficoll-Paque (Amersham Biosciences), washed with phosphate-buffered saline solution (PBS), and counted on a hemocytometer using the trypan blue dye exclusion method. These cells were then stimulated with 5 µg of phytohemagglutinin per ml and 10% T cell stimulation factor (T-stim, Collaborative Biomedical Sciences) for 48 h. CD4+ T lymphocytes were isolated from the activated PBMC by high gradient magnetic cell sorting with a VarioMACS (Miltenyi Biotec Inc.), according to the manufacturer's instructions. CD4+ T lymphocytes were then aliquoted into 24-well tissue culture plates at 1 × 106 cells and transduced with the indicated amount of recombinant virions.

Flow Cytometry-- Jurkat T cells were washed twice with PBS, resuspended in 100 µl of PBS containing 5 µg/ml phycoerythrin-labeled CXCR4 antibody, and incubated for 30 min at 4 °C. The cells were washed twice with ice-cold PBS and resuspended in PBS buffer. They were then analyzed by flow cytometry to determine the levels of surface expression of the receptor.

Chemokine and Cytokine Detection Assays-- Cell supernatants were assayed for secretion of the chemokines SDF-1alpha , MIP-1alpha or -1beta , and the cytokine IL-2 using enzyme-linked immunosorbent assay kits (Endogen Inc., Woburn, MA). Samples were assayed according to the manufacturer's protocol.

Treatment of Cells-- Jurkat T cells were starved for 1 h by placing them in RPMI medium supplemented with 0.5% fetal bovine serum. The cells were counted using the trypan blue dye exclusion method and resuspended to a concentration of 106 cells per ml. Cells were then treated with 50 ng/ml SDF-1alpha for the indicated times (0-60 min).

Chemotaxis Assays-- Chemotaxis assays were performed in duplicate using 5-µm pore filters (Transwell, 24-well cell clusters; Costar, Boston, MA). Briefly, 3 × 105 Jurkat cells or primary CD4+ T cells suspended in 300 µl of migration medium (RPMI + 0.5% bovine serum albumin) were loaded into each Transwell filter. Filters were then transferred to another well containing 600 µl of migration medium with the indicated concentrations of SDF-1alpha . The plates were incubated at 37 °C and 5% CO2 for 3 h. The upper chambers were removed, and the cells in the bottom chambers were washed with 1× PBS, resuspended, and quantitated using the trypan blue dye exclusion method. Results of the chemotaxis assays presented here are representative of multiple repetitions of the same experiment with similar results.

Immunoprecipitation and Western Blot Analysis-- For the immunoprecipitation studies, identical amounts of protein from each sample were incubated with different primary antibodies for 4 h at room temperature or overnight at 4 °C. Immunoprecipitations of the antibody-antigen complexes were performed by incubation for 2 h at 4 °C with 30 µl of protein A-Sepharose beads (10% suspension). Nonspecific bound proteins were removed by washing the Sepharose beads 3 times with radioimmunoprecipitation assay (RIPA) buffer containing 0.15 M NaCl, 0.05 M Tris-HCl, pH 7.2, 1% Triton X-100, and 0.1% SDS. Bound proteins were separated on NuPAGE 4-12% BisTris SDS-PAGE gels and then transferred to nitrocellulose membranes. The membranes were blocked with 5% nonfat milk protein and probed with the appropriate primary antibody for 2 h at room temperature or 4 °C overnight. Immunoreactive bands were visualized using horseradish peroxidase-conjugated secondary antibody and the enhanced chemiluminescent system (Amersham Biosciences). Data shown are representative of multiple experiments.

Phosphatidylinositol 3-Kinase (PI3K) Activity-- SDF-1alpha -treated cells, described above, were lysed in 300 µl of ice-cold lysis buffer (25 mM HEPES, 150 mM NaCl, 5 mM MgCl2, 0.2 mM EDTA, 0.1% Triton X-100 + 0.5 mM dithiothreitol, 0.1 mM phenylmethylsulfonyl fluoride, 2 µg/ml leupeptin, 4 µg/ml aprotinin). PI3K was immunoprecipitated using anti-p85 antibody. Immunoprecipitates were washed once with wash buffer 1 (25 mM HEPES, 150 mM NaCl, 5 mM MgCl2, 0.2 mM EDTA, 0.1% Triton X-100) and three times with wash buffer 2 (25 mM HEPES, 150 mM NaCl, 5 mM MgCl2, 0.2 mM EDTA). Samples were resuspended in 35 µl of reaction buffer (25 mM HEPES, 5 mM MgCl2, 0.2 mM EDTA), with 10 µg of phosphatidylinositol (Avanti Polar Lipids, Alabaster, AL), and the mixture was sonicated for 5 min. The reaction was initiated with the addition of 50 µM [gamma -32P]ATP (5 µCi) and carried out at 25 °C for 5 min. The reaction was stopped by adding 300 µl of MeOH, 1 M HCl (1:1 v/v). The lipids were extracted with 250 µl of CHCl3, and the mixture was vortexed and spun briefly. The aqueous phase was washed with CHCl3, and the samples were dried by Speed-Vac. Lipids were separated on silica gel-coated TLC plates. The plates were developed with CHCl3/CH3OH/H2O/NH4OH (28%), 90:90:7:20. The labeled products were visualized by autoradiography.

Related Adhesion Focal Tyrosine Kinase (RAFTK) Activity-- SDF-1alpha -treated cells, described above, were lysed in 300 µl of RIPA buffer with 1% sodium deoxycholate. RAFTK was immunoprecipitated from 500 µg of lysate using anti-RAFTK antibody. The immunoprecipitates were washed once with RIPA buffer and twice with 1× kinase buffer (25 mM HEPES, 20 mM MgCl2, 0.1 mM sodium orthovanadate). The reaction was carried out in 25 mM HEPES, 20 mM MgCl2, 0.1 mM sodium orthovanadate with 100 µg of poly(glutamine-tyrosine) (4:1), 0.8 mM ATP (6 µCi of [gamma -32P]ATP). After 30 min at room temperature, the reaction was terminated with SDS sample buffer, boiled for 3-5 min, and spun briefly to separate the beads. The supernatants were separated on a 10% SDS-PAGE gel. The gel was stained with Coomassie Blue, and the labeled products were visualized by autoradiography.

Statistical Analysis-- The migration experiments were repeated at least three times, with the data shown representative of all results. The data were analyzed for statistical significance using ANOVA (analysis of variance) two factor tests.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Expression of GFP or Nef-GFP Proteins in the Jurkat T Cell Line-- To investigate inducible expression of the introduced genes, GFP- or nef-GFP-expressing Jurkat T cells were cultured for 2 days in the absence of Tet to induce protein expression. Cell extracts were prepared from the expressing cells and subjected to Western blot analyses with anti-GFP antibody. The blot shows bands corresponding to GFP or the Nef-GFP fusion protein (Fig. 1A). When the membrane was stripped and reprobed for actin, equivalent amounts of protein in each lane were detected (Fig. 1A). These results confirmed the fidelity of the cell lines and the inducibility of the genes.


View larger version (29K):
[in this window]
[in a new window]
  		Fig. 1.   A, characterization of nef-expressing Jurkat T cell lines. After cell lysis, the proteins were separated as described and incubated with anti-GFP antibody. The bands representing GFP and HIV Nef are indicated based on known molecular weights (upper panel). Protein loading in each lane was determined to be equal by reprobing the membrane with anti-actin antibody (lower panel). B, Nef-mediated cytotoxicity. Cell growth was evaluated during induction of nef-GFP or GFP expression in Jurkat T cells by trypan blue dye exclusion method. C, nef-expressing Jurkat T cell migration in response to SDF-1alpha . Induced HIV nef-expressing cells show a significant decrease in SDF-1alpha -mediated chemotaxis in comparison with GFP-expressing control cells. Data are representative of several experiments with similar results, and values represent means; error bars represent means ± S.D. (p < 0.05 by ANOVA). D, effect of Nef on CXCR4 expression on the surface of the GFP- and nef-GFP-expressing Jurkat T cells. The level of CXCR4 expression on the surface of the Jurkat T cells was not altered by HIV-1 Nef. Solid black line and black dotted area represent GFP- and nef-GFP-expressing Jurkat T cells, respectively. The light gray area on the left indicates the isotype control. E, primary peripheral CD4+ T cell migration in response to SDF-1alpha . CD4+ T lymphocytes expressing HIV Nef show a significant decrease in SDF-1alpha -mediated chemotaxis in comparison with GFP-expressing cells. Data are representative of several experiments with similar results, and values represent means; error bars represent means ± S.D. (p < 0.05 by ANOVA). MOI, multiplicity of infection.

To exclude the effects of Nef on cytotoxicity in our experiments, cell growth was evaluated during induction of expression of the introduced genes by the trypan blue dye exclusion method. Growth kinetics of the GFP- or nef-GFP expressing cells were similar (Fig. 1B), indicating that Nef was not inhibitory for the cells.

Migration of nef-expressing T Cells in Response to SDF-1alpha -- The effects of Nef on chemotaxis in nef-expressing Jurkat T cells as compared with its effects in the control GFP-expressing cells were assessed by performing cell migration assays, as described above. The Jurkat cells that expressed HIV Nef (Nef-GFP) showed decreased levels of migration in response to SDF-1alpha in a dose-dependent manner (Fig. 1C, representative of several experiments). Migration levels never exceeded 8% of the total nef-expressing cells. At 100 ng/ml SDF-1alpha , control cells expressing GFP showed levels of migration ~3 times higher than the HIV nef-expressing cells. The difference in migration between the two cell populations was statistically significant (p < 0.05) using an ANOVA two-factor test.

Nef Effects on CXCR4 Expression on the Surface of T Cells-- The observed Nef-mediated inhibition of Jurkat T cell migration could be due to the down-modulation of CXCR4 expression on the surface of the cells. To investigate this possibility, the level of CD4 expression on the surface of the Jurkat clone was first examined. To this end, expression of GFP or nef-GFP in Jurkat T cells was induced by the removal of Tet, and the Jurkat T cells were stained with phycoerythrin-conjugated anti-CD4 antibody (Pharmingen). The expression of CD4 was then determined by flow cytometric analysis. We observed that expression of CD4 on the surface of the cells was down-modulated in the presence of Nef but not of GFP, consistent with previous reports (2) (data not shown). These data indicate that the Nef expressed in the cells was functional. The level of CXCR4 expression on the surface of the Jurkat T cells was then examined. As shown in Fig. 1D, the entire cell population expressed CXCR4, and the level of expression was not altered by HIV-1 Nef. These results demonstrate that the observed inhibition of T cell migration was not due to down-modulation of CXCR4 expression on the surface of the T cells.

Migration of Primary T Cells in Response to SDF-1alpha -- To confirm that the inhibitory effect of Nef was not restricted to the Jurkat T cell line, and to further confirm that the cell line would provide a model of pathophysiological effects in primary cells, nef was expressed in peripheral blood CD4+ T cells. To this end, PBMC were obtained from fresh whole blood by density gradient centrifugation with Ficoll-Paque (Amersham Biosciences), and CD4+ T lymphocytes were then isolated from the activated PBMC, as described under "Experimental Procedures." CD4+ T lymphocytes were then transduced with various amounts of recombinant virions. Similar to the Jurkat cells, cell viability in the AAV-nef-transduced cells was indistinguishable from that in the GFP-transduced CD4+ T cells, and the surface expression of CXCR4 was not down-modulated by Nef (data not shown). Two days after transduction, cell migration was assayed in the same manner as in the nef-expressing Jurkat cells, except that the migration was for 1 h instead of 3 h. Consistent with the results from the Jurkat T cells, the migration of primary CD4+ T lymphocytes was significantly inhibited in the presence of HIV-1 Nef (Fig. 1E). This reduction correlated with increasing titers of the AAV construct, indicating that HIV-1 Nef can inhibit the migration of primary peripheral blood CD4+ T cells in response to SDF-1alpha and that the inhibition was Nef-specific.

Chemokine and Cytokine Secretion by nef-expressing Cells-- The inhibition of migration by T cells expressing HIV nef could result from a potential increase in chemokine secretion that would compete with the exogenous ligand in the migration assay. To address this possibility, we assayed cell supernatants for several relevant chemokines, which have been reported to be secreted by macrophages (6). Neither the control nor HIV nef-expressing cells secreted the cognate ligand, SDF-1alpha , or the chemokines, MIP-1alpha and MIP-1beta (data not shown). Moreover, they also did not secrete different amounts of IL-2, a cytokine that can alter CXCR4 receptor expression (data not shown).

Intracellular Signaling in nef-expressing T Cell Lines-- HIV Nef is known to interact with several intracellular signaling molecules, including those that regulate the cytoskeletal apparatus and are relevant to chemotaxis (12-14, 17-19). We, therefore, examined several signaling molecules known to be involved in the SDF-1alpha signaling pathway. To determine whether there were any differences between the general phosphorylation patterns of the cell lines, cell lysates were Western immunoblotted with the phosphotyrosine-specific antibodies, anti-PY99 and anti-4G10. Several differences in the cell lines with regard to phosphorylation patterns were observed (Fig. 2A). The cells were then examined for changes in phosphorylation of the extracellular signal-related kinase (ERK), a signaling molecule known to be downstream of the CXCR4 receptor and recently reported to be modulated by HIV Nef in primary T cells (21). To assess the effect of Nef on ERK activation, SDF-1alpha -treated cell lysates were incubated with anti-phospho-ERK1/ERK2 antibodies. ERK1/ERK2 phosphorylation was detected most strongly in the HIV nef-expressing cells (Fig. 2B, lower panel), with levels several times that of the GFP-expressing cells (Fig. 2B, upper panel). Protein loading in each lane was determined to be equal by reprobing the membrane with anti-ERK1/ERK2 antibody.


View larger version (46K):
[in this window]
[in a new window]
  		Fig. 2.   A, phosphorylation patterns of nef-expressing Jurkat T cells. After cell lysis, the proteins were separated as described and incubated with anti-PY99 and anti-4G10 antibodies. Bands representing some of the differences in phosphorylation in the two cell lines are indicated. B, ERK1/ERK2 activation. Cells were treated with SDF-1alpha (50 ng/ml) for the indicated time points. After cell lysis, the proteins were separated as described and incubated with anti-phospho-ERK1 and anti-phospho-ERK2 antibodies. The ERK1/ERK2 activation in the HIV nef-expressing cells (lower panel) is significantly higher than that of the GFP-expressing cells (upper panel). Protein loading in each lane was determined to be equal by reprobing the membrane with anti-ERK1/ERK2 antibody. C, STAT1 activation. Cells were treated with SDF-1alpha (50 ng/ml) for the indicated time points. After cell lysis, the proteins were separated as described and incubated with anti-phospho-STAT1 antibody. Similar levels of STAT1 activation were observed for both cell lines.

To determine whether the changes observed in ERK1/2 activation in the HIV nef-expressing T cells reflected a global activation of multiple signaling pathways or was restricted to specific signaling molecules, we examined the activation status of STAT1 and another member of the MAP kinase family, p38. The SDF-1alpha -treated cell lysates were probed with anti-phospho-STAT1 antibody. Similar levels of STAT1 phosphorylation were observed for the GFP- and HIV nef-expressing T cells (Fig. 2C). Similarly, p38 was not differentially activated in the presence of Nef (data not shown). In addition, a recent publication that reported that HIV Nef increased ERK activity in primary T cells, also examined p38 and found it not to be activated by Nef in the same primary T cells (21). These results supported our data, which suggest specificity with regard to the effects of HIV Nef on intracellular signaling pathways.

Effect of Nef on Kinase Activities upon SDF-1alpha Activation-- PI3K is known to play an important role in cell migration. Previous studies (35-37) have shown PI3K to be an important intracellular regulator of cell migration. Thus, we studied the effect of HIV Nef on PI3K activity in nef-expressing cells as compared with control cells. PI3K activity was assayed as described above. The level of PI3K activity was unchanged in the HIV nef-expressing cells, despite treatment with SDF-1alpha (Fig. 3A, lower panel). In contrast, control GFP-expressing cells showed the expected increase in PI3K activity in response to SDF-1alpha treatment (Fig. 3A, upper panel). Densitometric scanning of this autoradiograph indicated distinct differences in PI3K activity between GFP- and nef-GFP-expressing Jurkat T cells (Fig. 3B).


View larger version (32K):
[in this window]
[in a new window]
  		Fig. 3.   A, PI3 kinase activity. Cells were treated with SDF-1alpha (50 ng/ml) for the indicated time points and assayed for PI3K activity as described. HIV nef-expressing cells (lower panel) showed a relatively constant level of PI3K activity. GFP-expressing cells (upper panel) showed increasing PI3K activity with SDF-1alpha treatment. B, quantitation of PI3K activity. Band intensities were quantitated using a densitometric scanner. C, RAFTK activity. Cells were treated with SDF-1alpha (50 ng/ml) for the indicated time points and assayed for RAFTK activity as described. HIV nef-expressing cells (lower panel) express a higher basal level of RAFTK activity than GFP-expressing cells (upper panel).

We next studied RAFTK, a platform kinase that coordinates upstream signals including those from Src kinases, phosphatases, and adapter proteins and transmits the signals downstream to the cytoskeletal apparatus and to transcriptional regulators such as ERK1 and ERK2 (34, 38). RAFTK is known to be an important component of the SDF-1alpha signaling pathway. Cells were assayed for the enzymatic activity of RAFTK, as described above. The HIV nef-expressing cells were found to have a higher basal level of RAFTK activity than the GFP-expressing cells (Fig. 3C, lower versus upper panel). Furthermore, the kinetics of the enzymatic activity of the HIV nef-expressing cells in response to SDF-1alpha treatment differed from those of the GFP-expressing cells. Taken together, these data suggest that changes in these kinases might be associated with the Nef-mediated effects on T cell migration.

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

This study is the first to our knowledge indicating that HIV Nef may modulate CD4+ T lymphocyte migration. This effect was observed in both model Jurkat T cells as well as in primary peripheral blood CD4+ lymphocytes in response to the physiological chemokine SDF-1alpha . Chemotaxis is an essential component of the immune response, wherein immune cells respond to invading pathogens by moving toward the site of infection along chemokine concentration gradients. This inhibition of cell migration in response to SDF-1alpha could contribute to HIV disease progression and pathogenicity.

Several different hypotheses were entertained with respect to how HIV Nef could abrogate the response to SDF-1alpha . Because HIV Nef is known to down-modulate important cell surface molecules like CD4 and MHC class I (2, 7), we considered whether CXCR4, the receptor for SDF-1alpha , might also be reduced in expression by Nef. We did not detect down-regulation of CXCR4, indicating that alterations in cognate receptor expression would not explain the abrogated chemotactic response. Similarly, if nef expression caused T cells to produce SDF-1alpha , then competition at the CXCR4 receptor between exogenous SDF-1alpha and the Nef-induced chemokine would alter migration. Whereas HIV nef expression has been reported to induce secretion of several chemokines in macrophages (6), we did not observe induction of SDF-1alpha , MIP-1alpha , or MIP-1beta secretion in T cells.

It has been reported that peripheral blood T cells need to be activated before they can migrate in response to inflammatory chemokines (39). Moreover, a recent report (40) showed that Zap 70 tyrosine kinase, an important signaling molecule for T cell activation, is involved in the migration of human T cells in response to the chemokine, SDF-1alpha . All of these data suggest that the activation state of T cells can modulate the chemotactic response. In contrast, another study reported that T cell receptor activation does inhibit chemotaxis to SDF-1 in Jurkat cells (41), although this was accompanied by a decrease in fluorescence intensity of the cell surface expression of CXCR4. This differs from our data. We do not, however, exclude the possibility that the decreased migration to SDF-1alpha of the nef-expressing cells may be (partially) related to T cell receptor activation by Nef, because CXCR4 receptor recycling (42) may account for the lack of change in CXCR4 expression on the nef-expressing Jurkat cells. Further experiments are required to address the role of activation on migration.

The role of Nef in T cell activation is also controversial. One report indicated that HIV-1 Nef induced transcriptional factors that were 97% identical to those observed after stimulation of Jurkat cells (43). However, other data indicated that Nef alone cannot activate resting T cells, which are manifested by IL-2 secretion from treated cells, but can activate the cells in combination with stimulation through the T cell receptor and the co-stimulus receptor (CD28) (9, 44). Our data show that HIV Nef did not induce significantly different amounts of IL-2 as compared with the control cells, suggesting that activation by this cytokine did not explain the observed phenomenon.

One possible explanation for Nef-mediated inhibition of T cell migration is its effects on intracellular signaling molecules. The different phosphorylation patterns, different basal levels of the enzymatic activities of key intracellular kinases, and their altered kinetics of response to SDF-1alpha could result in the failure to respond appropriately to the chemotactic stimulus. Such a response requires a highly ordered cascade of intracellular events, specifically, a physiological base line and induced changes in phosphorylation. For example, PI3K, whose lipid phosphorylation products act as second messengers throughout the cell, has been implicated in the activation of complex signaling cascades that mediate chemotaxis, among other cellular functions (34). Recent studies (36, 37) indicate that the disruption or removal of PI3K results in the dysregulation of leukocyte chemotaxis. Our data indicate that Nef can inhibit PI3K-mediated signaling cascades, which implies that PI3K may play an important role in Nef-mediated decreases in T cell migration. It is of note that the literature contains conflicting reports on Nef effects on PI3K, with some investigators finding inhibition (46), as we did, but others observing activation (47).

RAFTK kinase activity was also found to be changed in the presence of HIV Nef. The implications of RAFTK dysregulation could be profound, because this molecule signals downstream to the MAP kinase family, particularly ERK1/2 (48). Prior studies show that alterations in the regulated activation of RAFTK blunt the responses to several chemokines, including SDF-1alpha (49). Thus, alteration of RAFTK kinase activity in the presence of HIV Nef might also contribute to the abrogated T cell response to this chemokine observed in our experiments.

In addition, the kinases that we examined are known to affect cytoskeletal arrangement and focal adhesions (45, 48, 50), and thus are likely candidates for involvement in the chemotactic changes observed here. The higher basal activation of these kinases in the presence of HIV Nef may indicate a mechanism through which Nef abrogates the response of infected cells to SDF-1alpha treatment. In causing constitutive activation of kinases in the SDF-1alpha pathway, HIV Nef may preclude further activation of these kinases from having a significant effect upon the chemotactic response of the cells to SDF-1alpha treatment.

Furthermore, ERK1/ERK2 were differentially phosphorylated in the nef-expressing cell lines versus controls. Changes brought about by the activation of these potent transcriptional regulators could affect the migration of nef-expressing cells by altering the expression of genes whose products are necessary for the chemotactic response. Recently, Schrager et al. (21) reported specific activation of the ERK/MAP kinase signaling cascade in response to the expression of nef in primary T cells, which supports our findings. In that study, however, chemotaxis was not assessed. The effect of Nef on ERK and thus on gene expression relevant to chemotaxis is a subject for further study. In addition, future experiments will address whether Nef interacts directly with signaling molecules in the CXCR4 pathway or if their activation results from changes in other signaling molecules.

Improved understanding of how HIV gene products like Nef may alter key aspects of the immune response, like apoptosis as previously reported, and chemotaxis, as presented in this study, provides the basis for targeted therapeutic interventions in patients with AIDS. Such approaches may augment immune function by restoring physiological responses that are key in host defense.

    ACKNOWLEDGEMENTS

We thank Drs. Hava and Shalom Avraham for providing the RAFTK antibodies.

    FOOTNOTES

* This work was supported by the Diller, Von Furstenberg Family Foundation and National Institutes of Health Grants HL53745, HL61940, and DA5008.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger Both authors contributed equally to this work.

§ To whom correspondence should be addressed: Division of Experimental Medicine, Harvard Institutes of Medicine/BIDMC, 4 Blackfan Circle, Rm. 351, Boston, MA 02115. E-mail: jgroopma@caregroup.harvard.edu.

Published, JBC Papers in Press, September 26, 2002, DOI 10.1074/jbc.M204698200

    ABBREVIATIONS

The abbreviations used are: HIV, human immunodeficiency virus; AAV, adeno-associated virus; ECL, enhanced chemiluminescent; HRP, horseradish peroxidase; PBMC, peripheral blood mononuclear cells; PBS, phosphate-buffered saline; RIPA, radioimmunoprecipitation assay; PI3K, phosphatidylinositol 3-kinase; RAFTK, related adhesion focal tyrosine kinase; SDF-1alpha , stromal cell-derived factor-1alpha ; GFP, green fluorescent protein; BisTris, 2-[bis(2-hydroxyethyl)amino]-2-(hydroxymethyl)propane-1,3-diol; MHC, major histocompatibility complex; Tet, tetracycline; ANOVA, analysis of variance; MAP, mitogen-activated protein kinase; ERK, extracellular signal-regulated kinase; IL, interleukin.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Ringler, D. J., Mori, K., Panicali, D. L., Sehgal, P. K., Daniel, M. D., and Desrosiers, R. C. (1991) Cell 65, 651-662[CrossRef][Medline] [Order article via Infotrieve]
2. Ross, T. M., Oran, A. E., and Cullen, B. R. (1999) Curr. Biol. 9, 613-621[CrossRef][Medline] [Order article via Infotrieve]
3. Collins, K. L., Chen, B. K., Kalams, S. A., Walker, B. D., and Baltimore, D. (1998) Nature 391, 397-401[CrossRef][Medline] [Order article via Infotrieve]
4. Cullen, B. R. (1999) Nat. Med. 5, 985-986[CrossRef][Medline] [Order article via Infotrieve]
5. Du, Z., Lang, S. M., Sasseville, V. G., Lackner, A. A., Ilyinskii, P. O., Daniel, M. D., Jung, J. U., and Desrosiers, R. C. (1995) Cell 82, 665-674[CrossRef][Medline] [Order article via Infotrieve]
6. Swingler, S., Mann, A., Jacque, J. M., Brichacek, B., Sasseville, V. G., Williams, K., Lackner, A. A., Janoff, E. N., Wang, R., Fisher, D., and Stevenson, M. (1999) Nat. Med. 5, 997-1003[CrossRef][Medline] [Order article via Infotrieve]
7. Swigut, T., Iafrate, A. J., Muench, J., Kirchhoff, F., and Skowronski, J. (2000) J. Virol. 74, 5691-5701[Abstract/Free Full Text]
8. Luria, S., Chambers, I., and Berg, P. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 5326-5330[Abstract/Free Full Text]
9. Schrager, J., and Marsh, J. W. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 8167-8172[Abstract/Free Full Text]
10. Baur, A. S., Sawai, E. T., Dazin, P., Fantl, W. J., Cheng-Mayer, C., and Peterlin, B. M. (1994) Immunity 5, 373-384
11. Collette, Y., Chang, H. L., Cerdan, C., Chambost, H., Algarte, M., Mawas, C., Imbert, J., Burny, A., and Olive, D. (1996) J. Immunol. 156, 360-370[Abstract]
12. Lee, C. H., Leung, B., Lemmon, M. A., Zheng, J., Cowburn, D., Kuriyan, J., and Saksela, K. (1995) EMBO J. 14, 5006-5015[Medline] [Order article via Infotrieve]
13. Grzesiek, S., Bax, A., Clore, G. M., Gronenborn, A. M., Hu, J. S., Kaufman, J., Palmer, I., Stahl, S. J., and Wingfield, P. T. (1996) Nat. Struct. Biol. 3, 340-345[CrossRef][Medline] [Order article via Infotrieve]
14. Karn, T., Hock, B., Holtrich, U., Adamski, M., Strebhardt, K., and Rubsamen-Waigmann, H. (1998) Virology 246, 45-52[CrossRef][Medline] [Order article via Infotrieve]
15. Baur, A. S., Sass, G., Laffert, B., Willbold, D., Cheng-Mayer, C., and Peterlin, B. M. (1997) Immunity 6, 283-291[CrossRef][Medline] [Order article via Infotrieve]
16. Denny, M. F., Patai, B., and Straus, D. B. (2000) Mol. Cell. Biol. 20, 1426-1435[Abstract/Free Full Text]
17. Renkema, G. H., Manninen, A., and Saksela, K. (2001) J. Virol. 75, 2154-2160[Abstract/Free Full Text]
18. Wolf, D., Witte, V., Laffert, B., Blume, K., Stromer, E., Trapp, S., D'Aloja, P., Schürmann, A., and Baur, A. S. (2001) Nat. Med. 7, 1217-1224[CrossRef][Medline] [Order article via Infotrieve]
19. Renkema, G. H., and Saksela, K. (2000) Front. Biosci. 5, D268-D283[Medline] [Order article via Infotrieve]
20. Fackler, O. T., and Baur, A. S. (2002) Immunity 16, 493-497[CrossRef][Medline] [Order article via Infotrieve]
21. Schrager, J. A., der Minassian, V., and Marsh, J. W. (2002) J. Biol. Chem. 277, 6137-6142[Abstract/Free Full Text]
22. Cowley, S., Paterson, H., Kemp, P., and Marshall, C. J. (1994) Cell 77, 841-852[CrossRef][Medline] [Order article via Infotrieve]
23. Qiu, M., and Green, S. H. (1992) Neuron 9, 705-717[CrossRef][Medline] [Order article via Infotrieve]
24. Traverse, S., Gomez, N., Paterson, H., Marshall, C., and Cohen, P. (1992) Biochem. J. 288, 351-355[Medline] [Order article via Infotrieve]
25. Woo, C. H., You, H. J., Cho, S. H., Eom, Y. W., Chun, J. S., Yoo, Y. J., and Kim, J. H. (2002) J. Biol. Chem. 277, 8572-8578[Abstract/Free Full Text]
26. Weber, K. S., Ostermann, G., Zernecke, A., Schroder, A., and Klickstein, L. B. (2001) Mol. Biol. Cell. 12, 3074-3086[Abstract/Free Full Text]
27. Nagasawa, T., Kikutani, H., and Kishimoto, T. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 2305-2309[Abstract/Free Full Text]
28. Ganju, R. K., Brubaker, S. A., Meyer, J., Dutt, P., Yang, Y., Qin, S., Newman, W., and Groopman, J. (1998) J. Biol. Chem. 273, 23169-23175[Abstract/Free Full Text]
29. Cherla, R. P., and Ganju, R. K. (2001) J. Immunol. 166, 3067-3074[Abstract/Free Full Text]
30. Fernandis, A. Z., and Ganju, R. K. (2001) Science's STKE http://www.stke.org/cgi/content/full/OC_sigtrans;2001/91/pel
31. Hernandez-Lopez, H., Varas, A., Sacedon, R., Jimenez, E., Munoz, J. J., Zapata, A. G., and Vicente, A. (2002) Blood 99, 546-554[Abstract/Free Full Text]
32. Rollins, B. J. (1997) Blood 90, 909-928[Free Full Text]
33. Cyster, J. G. (1999) Science 286, 2098-2102[Abstract/Free Full Text]
34. Ganju, R. K., Dutt, P., Wu, L., Newman, W., Avraham, H., Avraham, S., and Groopman, J. (1998) Blood 91, 791-797[Abstract/Free Full Text]
35. Stephens, L., Ellson, C., and Hawkins, P. (2002) Curr. Opin. Cell Biol. 14, 203-213[CrossRef][Medline] [Order article via Infotrieve]
36. Hannigan, M., Zhan, L., Li, D., and Huang, C. (2002) Proc. Natl. Acad. Sci. U. S. A. 99, 3603-3608[Abstract/Free Full Text]
37. Kiosses, W. B., Daniels, R. H., Otey, C., Bokoch, G. M., and Schwartz, M. A. (1999) J. Cell Biol. 147, 831-844[Abstract/Free Full Text]
38. Brown, A., Wang, X., Sawai, E., and Cheng-Mayer, C. (1999) J. Virol. 73, 9899-9907[Abstract/Free Full Text]
39. Moser, B., and Loetscher, P. (2001) Nat. Immunol. 2, 123-128[CrossRef][Medline] [Order article via Infotrieve]
40. Ottoson, N. C., Pribila, J. T., Chan, A. S., and Shimizu, Y. (2001) J. Immunol. 167, 1857-1861[Abstract/Free Full Text]
41. Peacock, J. W., and Jirik, F. R. (1999) J. Immunol. 162, 215-223[Abstract/Free Full Text]
42. Foster, R., Kremmer, E., Schubel, A., Breiffeld, D., Kleinschmidt, A., Nerl, C., Bernhardt, G., and Lipp, M. (1998) J. Immunol. 160, 1522-1531[Abstract/Free Full Text]
43. Simmons, A., Aluvihare, V., and McMichael, A. (2001) Immunity 14, 763-777[CrossRef][Medline] [Order article via Infotrieve]
44. Wang, J. K., Kiyokawa, E., Verdin, E., and Trono, D. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 394-399[Abstract/Free Full Text]
45. Zhao, Z. S., Manser, E., Loo, T. H., and Lim, L. (2000) Mol. Cell. Biol. 20, 6354-6363[Abstract/Free Full Text]
46. Graziani, A., Galimi, F., Medico, E., Cottone, E., Gramaglia, D., Boccaccio, C., and Comoglio, P. M. (1996) J. Biol. Chem. 271, 6590-6593[Abstract/Free Full Text]
47. Schibeci, S. D., Clegg, A. O., Biti, R. A., Sagawa, K., Stewart, G. J., and Williamson, P. (2000) AIDS 14, 1701-1707[CrossRef][Medline] [Order article via Infotrieve]
48. Avraham, H., Park, S. Y., Schinkmann, K., and Avraham, S. (2000) Cell. Signal. 12, 123-133[CrossRef][Medline] [Order article via Infotrieve]
49. Dutt, P., Wang, J. F., and Groopman, J. E. (1998) J. Immunol. 161, 3652-3658[Abstract/Free Full Text]
50. Jimenez, C., Portela, R. A., Mellado, M., Rodriguez-Frade, J. M., Collard, J., Serrano, A., Martinez, A. C., Avila, J., and Carrera, A. C. (2000) J. Cell Biol. 151, 249-262[Abstract/Free Full Text]

Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Virol.Home page
S. Venzke, N. Michel, I. Allespach, O. T. Fackler, and O. T. Keppler
Expression of Nef Downregulates CXCR4, the Major Coreceptor of Human Immunodeficiency Virus, from the Surfaces of Target Cells and Thereby Enhances Resistance to Superinfection
J. Virol., November 15, 2006; 80(22): 11141 - 11152.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
K. Hrecka, T. Swigut, M. Schindler, F. Kirchhoff, and J. Skowronski
Nef Proteins from Diverse Groups of Primate Lentiviruses Downmodulate CXCR4 To Inhibit Migration to the Chemokine Stromal Derived Factor 1
J. Virol., August 15, 2005; 79(16): 10650 - 10659.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Poggi, R. Carosio, D. Fenoglio, S. Brenci, G. Murdaca, M. Setti, F. Indiveri, S. Scabini, E. Ferrero, and M. R. Zocchi
Migration of V{delta}1 and V{delta}2 T cells in response to CXCR3 and CXCR4 ligands in healthy donors and HIV-1-infected patients: competition by HIV-1 Tat
Blood, March 15, 2004; 103(6): 2205 - 2213.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. Z. Fernandis, R. P. Cherla, and R. K. Ganju
Differential Regulation of CXCR4-mediated T-cell Chemotaxis and Mitogen-activated Protein Kinase Activation by the Membrane Tyrosine Phosphatase, CD45
J. Biol. Chem., March 7, 2003; 278(11): 9536 - 9543.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/48/46079    most recent
M204698200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Choe, E. Y.
Right arrow Articles by Park, I.-W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Choe, E. Y.
Right arrow Articles by Park, I.-W.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg